Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder
Article Abstract:
The most prominent characteristic of bipolar affective disorder is one or more manic episodes which alternate with one or more depressive episodes. Lithium therapy is the treatment of choice for this condition, but as many as 40 percent of bipolar patients do not respond to or tolerate this drug well. Previous studies have indicated that patients with rapid-cycling bipolar disorder represent a significant proportion of those who are resistant to this treatment. Carbamazepine has been used as a substitute and, although it has shown success with manic symptoms, it is not as effective in relieving the symptoms of depression. A second alternative treatment that has been suggested is valproate, and the efficacy of this drug in 55 bipolar patients was assessed. The subjects were all diagnosed with rapid-cycling bipolar disorder and had been resistant to other treatments. The patients were given valproate in combination with other drugs (35 subjects) or alone (20 subjects) and were followed over a period of about eight months. In the 20 patients receiving valproate alone, 89 percent exhibited a marked improvement during acute manic episodes, while only 57 percent showed a marked response during depressive episodes. The results confirmed previous studies that indicated valproate was effective in relieving manic symptoms, but had only a moderate effect on the symptoms of depression. The best method of treating depressive symptoms associated with this disorder is still not clear; more research is needed to determine whether a single drug or a combination therapy is the best approach. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: American Journal of Psychiatry
Subject: Psychology and mental health
ISSN: 0002-953X
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania
Article Abstract:
Trichotillomania is a psychiatric disorder characterized by compulsive hair pulling. Because this disorder shows similarities to obsessive-compulsive disorder, drugs that are useful in treating obsessive-compulsive disorder have been suggested for use in treating trichotillomania. Fluoxetine, an antiobsessional agent, has been reported useful in treating the disorder in a few studies, but most of the studies involved open trials. To further examine the effectiveness of fluoxetine in treating hair pulling, a double-blind, placebo-controlled crossover study involving 21 adult chronic hair pullers was conducted. The subjects were given either fluoxetine or a placebo for six weeks, followed by five weeks of neither, and then six more weeks of the opposite substance. Fifteen subjects completed the study and one subject completed 16 weeks of the study before dropping out because of a drug reaction. Weekly ratings of hair pulling, urge to pull hair, number of hair pulling episodes, and amount of hair pulled per week were not significantly changed during either the fluoxetine or placebo treatment phases. These results indicated that with short-term use, fluoxetine is not effective in treating trichotillomania. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: American Journal of Psychiatry
Subject: Psychology and mental health
ISSN: 0002-953X
Year: 1991
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Alexithymia and body image in adult outpatients with binge eating disorder. Pathways to help-seeking in bulimia nervosa and binge-eating problems: A concept mapping approach
- Abstracts: Observed emotional involvement and overinvolvement in families of patients with bipolar disorder. Development and validation of an observational coding system for emotional overinvolvement
- Abstracts: Controlled trial of a brief cognitive-behavioral intervention in adolescent patients with depressive disorders
- Abstracts: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Serotonergic measures in the brains of suicide victims: 5-HT(subscript 2) binding sites in the frontal cortex of suicide victims and control subjects
- Abstracts: Time-related predictors of suicide in major affective disorder. Gender differences in the clinical features of unipolar major depressive disorder